SEC Filings
Legend Biotech Takes Two Oral Talks And Four Posters To ASH, Led By Early In Vivo CAR-T Data
The December meeting program covers CARVYKTI follow-up, an in vivo CAR-T study and an allogeneic lymphoma candidate.
Legend Biotech (LEGN) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
The December meeting program covers CARVYKTI follow-up, an in vivo CAR-T study and an allogeneic lymphoma candidate.
SEC Filings
Legend Biotech plans a U.S. Phase 1/2 study of LB2501 in relapsed or refractory B-cell cancers, without lymphodepleting chemotherapy.